Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Strong Recent Returns And Oncology Pipeline Focus [Yahoo! Finance]
Jazz Pharmaceuticals Touts Record $4.3B 2025 Revenue, Reaffirms 2026 Outlook at Conference [Yahoo! Finance]
Jazz Pharmaceuticals plc (JAZZ) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript [Seeking Alpha]
Jazz Pharmaceuticals (JAZZ) was upgraded by Raymond James Financial, Inc. to "moderate buy".
Jazz Pharmaceuticals (JAZZ) was given a new $227.00 price target by Raymond James Financial, Inc..